P. Valk
3 Papers
1 Citations
P. Valk is an academic researcher. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 3 publications.
Chat about Author
Papers
S130: npm1 mutated aml: impact of co-mutational patterns - results of the european harmony alliance
Alberto Hernandez-Sanchez,Á. Villaverde-Ramiro,J. Martinez Elicegui,T. González,Alisha Benner,Eric Sträng,Giorgia Castellani,Caroline A. Heckman,Jurjen Versluis,María Abáigar,Marta Anna Sobas,Raul Azibeiro,L. Tur,P. Valk,Klaus H. Metzeler,Rodriguez Ayala,Daniele Dall'Olio,Jesse M. Tettero,Jorge Martínez-López,Hervé Dombret,Marta Pratcorona,F. Damm,Ken I. Mills,Jillian Mayer,Christian Thiede,Maria Teresa Voso,Guillermo Sanz,Filipe Calado,Konstanze Döhner,Verena I. Gaidzik,Michael Heuser,Torsten Haferlach,Amin T. Turki,Dirk Reinhardt,R. Villoria Medina,M van Speybroeck,Renate Schulze-Rath,Martje Barbus,John Butler,J.M. Hernández Rivas,B. J. Huntly,Gert J. Ossenkoppele,Hartmut Döhner,Lars Bullinger +43 more
TL;DR: Multivariate analysis of OS in N PM1mut AML identified the following independent prognostic factors: NPM1mut model (taking favorable group as reference, HR 1.6 for intermediate and HR 2.7 for adverse group, p<0.001); secondary or therapy-related AML; WBC at diagnosis >100x103/μL; and age >60 years.
2
P404: prognostic impact of cebpa-mutational subgroups in adult aml – results of a large metaanalysis in more than 1000 cebpa-mutant patients
J. Georgi,Sebastian Stasik,Michael Kramer,Christoph Röllig,Torsten Haferlach,P. Valk,David C. Linch,Tobias Herold,Nicolas Duployez,Franziska Taube,Uwe Platzbecker,Hubert Serve,Claudia D. Baldus,Carsten Müller-Tidow,Claudia Haferlach,Manja Meggendorfer,Sarah Koch,Emma Boertjes,R. Hills,A. Burnett,Gerhard Ehninger,Klaus H. Metzeler,Maja Rothenberg-Thurley,Annika Dufour,Hervé Dombret,Cécile Pautas,Laurène Fenwarth,Martin Bornhäuser,Rosemary E. Gale,Christian Thiede +29 more
TL;DR: In this article , a meta-analysis involving detailed sequencing data from 1010 CEBPA-mutant pts was performed, and the prognostic impact of different mutations was confirmed in multivariable analyses taking into account the individual study groups.
P406: enhanced significance of flt3-itd residual disease detection on treatment outcome in acute myeloid leukemia
Tim Grob,Marcus Sanders,Carina Vonk,François G. Kavelaars,Melissa Rijken,Dirkje W Hanekamp,Patrycja L Gradowska,Jacqueline Cloos,Yngvar Fløisand,Marinus van Marwijk Kooy,M. Manz,Gert J. Ossenkoppele,Lidwine L W Tick,Violaine Havelange,Bob Löwenberg,Mojca Jongen-Lavrencic,P. Valk +16 more
TL;DR: In this paper , the impact of FLT3-internal tandem duplications detection on treatment outcome in a cohort of newly diagnosed patients with acute myeloid leukemia (AML) in the context of current prognostic factors at diagnosis and other MRD measurements during therapy, including mutant NPM1 and multiparameter flow cytometry (MFC).